Table 2. Distribution of clinicopathological features.
| Features | First- or second-line immunotherapy, n (%) | Third- or later line immunotherapy, n (%) | P value |
|---|---|---|---|
| Age (years) | 0.03 | ||
| ≤65 | 57 (44.2) | 70 (57.9) | |
| >65 | 72 (55.8) | 51 (42.1) | |
| Sex | 0.47 | ||
| Female | 23 (17.8) | 26 (21.5) | |
| Male | 106 (82.2) | 95 (78.5) | |
| Neoplasm staging | <0.001 | ||
| ≤ III* | 65 (50.4) | 33 (27.3) | |
| > III | 64 (49.6) | 88 (72.7) | |
| Pathological type | 0.64 | ||
| SCLC | 22 (17.1) | 18 (14.9) | |
| NSCLC | 107 (82.9) | 103 (85.1) | |
| Smoking history | 0.31 | ||
| Yes | 91 (70.5) | 78 (64.5) | |
| No | 38 (29.5) | 43 (35.5) | |
| Alcohol history | <0.001 | ||
| Yes | 20 (15.5) | 51 (42.1) | |
| No | 109 (84.5) | 70 (57.9) |
*, the TNM staging was based on the AJCC 8th edition (when the initial diagnosis). SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; AJCC, American Joint Committee on Cancer.